1AD AdAlta Ltd
- 0.025
- 0.0000.00%
AdAlta Ltd News
AdAlta Ltd. Reports Major Shareholder Changes
AdAlta Ltd Announces Quotation of New Securities
AdAlta Ltd Advances Drug Pipeline Amid Investment Risks
AdAlta Signs Master Services Agreement With Cell Therapies; Shares Up 4%
Biotechnology company AdAlta (ASX:1AD) and Cell Therapies entered into a master services agreement designating Cell Therapies as the company's preferred manufacturing partner of cellular immunotherapi
AdAlta Ltd Applies for New ASX Securities Quotation
AdAlta Ltd. Expands Investment and Partnerships
AdAlta Ltd. Seeks ASX Expansion With New Securities
AdAlta Ltd Hosts Investor Webinar on Growth Funding
AdAlta Secures Up to AU$3.7 Million for MOU, I-body Programs
AdAlta (ASX:1AD) has secured up to AU$3.7 million from New Zealand Life Sciences Capital and Meurs Investment to accelerate its recent memorandum of understanding with SYNthesis BioVentures and to pro
AdAlta Ltd Secures Loan Repayment Extension
AdAlta Ltd. Raises $3.7 Million for Strategic Growth
AdAlta Ltd. Advances Fibrosis Treatment, Secures Funding
AdAlta Ltd Expands Securities on ASX
AdAlta Ltd Announces Option Exercise Opportunity
AdAlta Ltd Advances Cellular Immunotherapy Innovations
AdAlta Explores Cancer Immunotherapies Joint Venture for Western Market
AdAlta (ASX:1AD) signed a memorandum of understanding with SYNthesis BioVentures Fund to provide innovative cellular immunotherapies from Asia to the Western market through a joint entity, according to a Monday filing with the Australian bourse.
AdAlta Ltd: Pioneering Next-Gen Cancer Immunotherapies
AdAlta's AD-214 Demonstrates Safety and Efficacy Potential for Fibrotic Disease Treatment
Top-line results from a Phase I extension study of AdAlta’s (ASX: 1AD) lead asset AD-214 in the treatment of fibrotic disease have established the safety, tolerability and bioavailability of a target dose for planned Phase II clinical studies.
Stocks of the Hour: Atomo Diagnostics, AdAlta, Aruma Resources
To register for Friday's webinar click here.Atomo Diagnostics (ASX:AT1) has announced securing purchase orders from Viatris Healthcare Pty Ltd for approximately AUD $970,000 worth of HIV Self-Tests, m
AdAlta-La Trobe University Collab Discovers New I-Bodies for Malaria Treatment; Shares Climb 4%
AdAlta's (ASX:1AD) research collaboration with La Trobe University discovered a new family of i-bodies that protect cells from invasion by malaria and related parasites, the drug development firm said Tuesday.
Analysis
Price Target
No Data
